Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer
Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the feasibility and efficacy outcomes of neoadjuvant
modified FOLFIRINOX and postoperative gemcitabine in patients with borderline resectable
pancreatic cancer.